GT Biopharma Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND>

from ABN Newswire Finance Video · host ABN Newswire

GT Biopharma, Inc. (NASDAQ:GTBP) continues to advance its platform-based immuno-oncology strategy following recent FDA clearance of an Investigational New Drug (IND) application for GTB-5550 targeting solid tumors.>

Episode metadata supplied by the publisher feed · Published Feb 9, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

GT Biopharma Advances Platform Immuno-Oncology Strategy with FDA-Cleared Solid Tumor IND>

0:00 7:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of ABN Newswire Finance Video?

This episode is 7 minutes long.

When was this ABN Newswire Finance Video episode published?

This episode was published on February 9, 2026.

Can I download this ABN Newswire Finance Video episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!